K. Rogers

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Kevin B. Rogers, Kevin R. Rogers, Kevin Rogers, Kevin R Rogers, K. Rogers
Publication record
58 papers · 1,944 citations · H-index 8

PAPERS

Total Ischemic Event Reduction with Rivaroxaban after Peripheral Arterial Revascularization in the VOYAGER PAD Trial.
202140 citationsauthor #11
3:27 PM Abstract No. 45 Evolution in national endovascular management of femoral-popliteal artery disease: an analysis of the 2011 to 2017 Medicare data
20200 citationsauthor #8
4:12 PM Abstract No. 316 Variations in endovascular management of infrapopliteal arterial disease: national trends from the Medicare procedure database
20200 citationsauthor #8
3:54 PM Abstract No. 48 National trends in endovascular management of iliac arterial disease: insights from the Medicare population
20200 citationsauthor #8
The utilization of intravascular lithotripsy to facilitate transcarotid artery stenting in a nonagenarian patient.
20200 citationsauthor #2
RISK AND COSTS AFTER PERIPHERAL REVASCULARIZATION IN PATIENTS WITH PERIPHERAL ARTERY DISEASE WITH AND WITHOUT DIABETES
20200 citationsauthor #6
Anti-platelet and anti-hypertension medication use in patients with fibromuscular dysplasia: Results from the United States Registry for Fibromuscular Dysplasia
201528 citationsauthor #10
Effect of tirasemtiv, a selective activator of the fast skeletal muscle troponin complex, in patients with peripheral artery disease
20148 citationsauthor #5
Blood pressure response to renal artery stenting in 901 patients from five prospective multicenter FDA‐approved trials
201437 citationsauthor #4
Response to McDermott.
20141 citationsauthor #2
Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population.
2014462 citationsauthor #6
PREDICTORS OF CLINICAL BENEFIT OF RENAL ARTERY STENTING IN 1,003 PATIENTS IN SIX PROSPECTIVE MULTICENTER TRIALS
20130 citationsauthor #2
Figure 1, Analytic Framework and Key Questions
20110 citationsauthor #7
Author response: B-type natriuretic peptide for cardiovascular events independent of left ventricular end-diastolic pressure
20100 citationsauthor #1
Evidence Table 6, [Cohort Studies of Homocysteine as a Risk Factor for Coronary Heart Disease].
20090 citationsauthor #7
Figure 13, [Risk Ratio of CHD Associated with C-Reactive Protein, by Selected Characteristics].
20090 citationsauthor #7
Table 8, [Assessment of the Strength of Evidence and Magnitude of Benefit].
20090 citationsauthor #7
Figure 4, [Risk Ratios of CHD Associated with Periodontal Disease, by Selected Characteristics].
20090 citationsauthor #7
Evidence Table 2, [Impaired Fasting Glucose as a Risk Factor for Coronary Heart Disease].
20090 citationsauthor #7
Figure 7, [Study Characteristics and Risk Ratio...].
20090 citationsauthor #7
[Table, Ankle Brachial Index].
20090 citationsauthor #7
[Table, Electron Beam Tomography].
20090 citationsauthor #7
Evidence Table 7, [Nested Case Control Studies of Homocysteine as a Risk Factor for Coronary Heart Disease].
20090 citationsauthor #7
Table 6, [Prevalence of Coronary Artery Calcification (CAC) Scores by Framingham Risk Group].
20090 citationsauthor #7
Evidence Table 5, [Electron Beam Computed Tomography Score as a Risk Factor for Coronary Heart Disease].
20090 citationsauthor #7
Risk Distribution Table 14, [Distribution of Expected CHD Events...].
20090 citationsauthor #7
[Table, Lipoprotein(a)].
20090 citationsauthor #7
Emerging Risk Factors for Coronary Heart Disease: A Summary of Systematic Reviews Conducted for the U.S. Preventive Services Task Force
2009430 citationsauthor #5
Figure 2, [Sequential Evaluation Scheme for Each Risk Factor].
20090 citationsauthor #7
Risk Distribution Table 11, [Distribution of CRP Levels and...].
20090 citationsauthor #7
Evidence Table 1, [White Blood Cell Count as a Risk Factor for Coronary Heart Disease].
20090 citationsauthor #7
Table 3, [Cohorts in which CHD Novel Risk Factors Were Studied].
20090 citationsauthor #7
Evidence Table 10, [Nested Case Control Studies of C Reactive Protein as a Risk Factor for Coronary Heart Disease].
20090 citationsauthor #7
Evidence Table 3, [Periodontal Disease as a Risk Factor for Coronary Heart Disease].
20090 citationsauthor #7
Evidence Table 4, [Carotid Intima-Media Thickness as a Risk Factor for Coronary Heart Disease].
20090 citationsauthor #7
Figure 6, [Subgroup Analysis of Risk Ratio...].
20090 citationsauthor #7
Table 2, [Emerging Risk Factors].
20090 citationsauthor #7
Figure 12, [Risk Ratio of CHD Associated with C-Reactive Protein (1.0 – 3.0 mg/L vs <1.0 mg/L)].
20090 citationsauthor #7
[Table, C-reactive Protein].
20090 citationsauthor #7
Risk Distribution Table 13, [Risk for First Hard CHD...].
20090 citationsauthor #7
Figure 14, [Occurance of a First Coronary...].
20090 citationsauthor #7
Evidence Table 9, [Cohort Studies of C-Reactive Protein as a Risk Factor for Coronary Heart Disease].
20090 citationsauthor #7
Risk Distribution Table 15, [Clinical Characteristics of US Men...].
20090 citationsauthor #7
Figure 3, [Study Characteristics and Risk Ratios...].
20090 citationsauthor #7
Screening for Intermediate Risk Factors for Coronary Heart Disease
200917 citationsauthor #7
Figure 8, [Risk Ratio of CHD Associated...].
20090 citationsauthor #7
Evidence Table 8, [Lipoprotein(A) as a Risk Factor for Coronary Heart Disease].
20090 citationsauthor #7
C-Reactive Protein as a Risk Factor for Coronary Heart Disease: A Systematic Review and Meta-analyses for the U.S. Preventive Services Task Force
2009568 citationsauthor #4
Table 1, [ATP-III Risk Categories].
20090 citationsauthor #7
[Table, Carotid Intima-media Thickness].
20090 citationsauthor #7
Table 4, [Frequency of Events in Framingham 10-20% Risk Group by CAC Score].
20090 citationsauthor #7
Performing a myocardial biopsy in a cardiac transplant patient with a persistent left superior vena cava
20091 citationsauthor #1
[Table, White Blood Cell Count].
20090 citationsauthor #7
[Table, Impaired Fasting Glucose].
20090 citationsauthor #7
[Table, Periodontal Disease].
20090 citationsauthor #7
Table 5, [Scores for Framingham Risk Facotrs and hsCRP].
20090 citationsauthor #7
U.S. Preventive Services Task Force Quality Rating Criteria
20085 citationsauthor #7
For Personal Use. Mass Reproduce Only with Permission from Mayo Clinic Proceedings. for Personal Use. Mass Reproduce Only with Permission from Mayo Clinic Proceedings. Homocysteine Level and Coronary Heart Disease Incidence: a Systematic Review and Meta-analysis
year unknown350 citationsauthor #3

TIMELINE

2008 5 citations

2009 1,016 citations

2010 0 citations

2011 0 citations

2013 0 citations

2014 508 citations

2015 28 citations

2020 0 citations

2021 40 citations

Unknown 350 citations

COAUTHOR MAP

CONCEPT FOOTPRINT